No Patient Workplace Protections — West Virginia’s At-Will Trap

Last verified: May 2026

The Statutory Silence

When the Legislature drafted Senate Bill 386 in 2017, it deliberately omitted any private-employer non-discrimination clause. The Act — codified at W. Va. Code §§ 16A-1-1 through 16A-15-1 — protects a registered patient from state arrest and prosecution for cannabis-related conduct authorized by the program, but it does not obligate a West Virginia employer to ignore a positive cannabis test, accommodate medical use, or refrain from termination for off-duty use. Sen. Richard Ojeda (D-Logan) and Sen. Mike Woelfel (D-Cabell) accepted the omission as the price of getting Senate President Bill Cole and a Republican-leaning chamber to permit a floor vote at all. See SB 386 enactment.

What a West Virginia Employer May Do

Because the Mountain State remains a default at-will jurisdiction (Harless v. First Nat’l Bank, 162 W. Va. 116 (1978), establishes only narrow public-policy exceptions, none of which the West Virginia Supreme Court of Appeals has extended to medical cannabis), an employer in West Virginia may lawfully:

• Refuse to hire a job applicant on the basis of a positive pre-employment cannabis screen, even if the applicant is a registered patient with a valid Office of Medical Cannabis ID card
• Terminate an employee for off-duty cannabis use detected through random, post-accident, or reasonable-suspicion testing — with no obligation to inquire whether use was medical or recreational
• Maintain a "drug-free workplace" policy (often required for federal contractors under the Drug-Free Workplace Act of 1988) that categorically excludes registered medical patients from employment
• Decline to provide a reasonable accommodation under the West Virginia Human Rights Act (W. Va. Code § 5-11-1 et seq.), because state-licensed medical cannabis use is not a protected activity and West Virginia courts have not recognized cardholder status as a disability proxy
• Refuse to engage in the interactive accommodation process used in employment-discrimination cases, because the underlying right to use does not exist as an employment-law protection

The Sister-State Contrast

West Virginia’s posture is unusually weak among medical-cannabis states. Pennsylvania’s Medical Marijuana Act (Act 16 of 2016, 35 P.S. § 10231.2103) bars an employer from discharging or discriminating against a certified patient solely on the basis of patient status — commonly described as the "lift-the-veil" protection — and Pennsylvania courts have enforced it (see Palmiter v. Commonwealth Health Sys., 260 A.3d 967 (Pa. Super. 2021)). New Jersey’s CREAMM Act (N.J. Stat. § 24:6I-52) prohibits adverse employment action based solely on cannabis presence in a drug test absent contemporaneous impairment. New York Labor Law § 201-d, California Government Code § 12954 (effective January 1, 2024), and Connecticut Public Act 21-1 § 122 each shield off-duty use to varying degrees. Maryland’s Cannabis Reform Act preserves employer prerogative more broadly but limits adverse action against medical patients in some safety-non-sensitive roles.

The Mountain State sits with Florida, Kentucky, North Carolina (no medical), and a handful of others on the no-protection side of that line. A registered West Virginia patient who commutes to a job in Hagerstown, Maryland or Pittsburgh, Pennsylvania may well have stronger workplace protections at work than at home. See Maryland cross-border; see Pennsylvania cross-border.

Federal Schedule III Does Not Change This

The DEA’s April 28, 2026 final rule moving cannabis from Schedule I to Schedule III (91 Fed. Reg. 22714) does not, on its own, create any West Virginia state-law workplace protection. Schedule III status removes some federal tax-and-research disabilities but does not pre-empt private-employer drug-testing programs, federal Drug-Free Workplace Act obligations, or U.S. Department of Transportation testing rules. A registered patient in Charleston, Morgantown, or Martinsburg who tests positive after April 28, 2026 retains exactly the same lack of state-law protection she had on April 27, 2026. See CDL/DOT/FMCSA page.

The 3 ng/mL DUI Trap Compounds the Problem

West Virginia’s § 17C-5-2(d)(2) per se DUI threshold — 3 nanograms per milliliter of active delta-9-THC in whole blood — survives in a patient’s bloodstream long after impairment subsides for chronic medical users. A registered patient who legally medicates Sunday evening can fail a Tuesday-morning random workplace drug test, fail a Tuesday-afternoon post-accident blood draw under § 17C-5-2, and lose both her job and her driver’s license in the same week without ever being impaired at work. See 3 ng/mL patient trap.

What Patients Can (and Cannot) Negotiate

Registered patients in the Mountain State have limited but non-zero options. Some employers — particularly those in non-safety-sensitive roles in Morgantown, Charleston’s Kanawha Valley, and the Eastern Panhandle — will accommodate a registered patient as a matter of policy even though state law does not require it. Public-sector employers vary widely; the State of West Virginia maintains a drug-testing policy under W. Va. Code § 21-1E that excludes safety-sensitive personnel from cannabis-positive accommodation. Federal employers and federal contractors operating on West Virginia soil — the FBI CJIS Division in Clarksburg, the Veterans Health Administration in Beckley/Clarksburg/Huntington/Martinsburg, the Federal Bureau of Prisons facilities at FCI Beckley, FCI Hazelton, and FPC Alderson — are categorically barred from accommodating cannabis use of any kind under federal law. See FBI CJIS / clearances page.

The Mountain State Workplace Reality

• West Virginia is at-will; the Medical Cannabis Act provides no employment non-discrimination clause.
• An employer in the Mountain State may refuse to hire, fire, or discipline a registered patient for off-duty use detected by a workplace drug test.
• Pennsylvania, New Jersey, New York, California, and Connecticut all offer stronger patient employment protections than West Virginia.
• The April 28, 2026 federal Schedule III rescheduling does not pre-empt private-employer drug-testing programs.
• The 3 ng/mL per se DUI threshold means a positive workplace test can also produce a license suspension on the same conduct.
• Federal contractors and federal agencies in West Virginia — FBI CJIS, the VA, BOP — are independently barred from accommodating cannabis use.